Login to the AD Community

Forgot your password?

Close







Search the Duchennepedia

Popular Tags

Actions

Create a new article


Articles tagged with GSK

2-'O-methyl antisense oligos (PS) targeting exon 51.

BACKGROUND:Duchenne’s muscular dystrophy is associated with severe, progressive muscle weakness and typically leads to death between the ages of 20 and 35 years. By inducing specific exon sk...

Tags: myofibers, biopsy, exon skipping, exon 51, prosensa, GSK, clinical trials.

GSK2402968 Clinical Development Programme Update

Forty-Eight Week Follow-Up Data from a Phase I/IIa Extension Study of PRO051/GSK2402968 in Subjects with Duchenne Muscular DystrophyThe following Phase I/IIa extension study results were presented...

Tags: Duchenne, DMD, GSK, Duchenne Muscular Dystrophy.

Prosensa announces further exon skipping drugs for Duchenne Muscular Dystrophy

Prosensa from the Netherlands have announced their programme for taking Exon Skipping forward. The Dutch company in collaboration with GSK have developed an exon skipping drug based upon 2’O...

Tags: duchenne, exon skipping, duchenne muscular dystrophy, prosensa, gsk, oligonucleotides, clinical trials.